Benitec Biopharma (NASDAQ:BNTC) Price Target Raised to $18.00 at JMP Securities

Benitec Biopharma (NASDAQ:BNTC) had its price objective upped by JMP Securities from $16.00 to $18.00 in a research report released on Monday morning, Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.

A number of other research analysts have also issued reports on BNTC. Guggenheim assumed coverage on Benitec Biopharma in a report on Thursday, September 12th. They issued a buy rating and a $17.00 target price for the company. Leerink Partners initiated coverage on Benitec Biopharma in a research note on Monday, July 22nd. They issued an outperform rating and a $13.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of Benitec Biopharma to a strong-buy rating in a research note on Monday, July 22nd. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of Buy and an average target price of $19.50.

Benitec Biopharma Stock Down 6.4 %

Benitec Biopharma stock opened at $10.16 on Monday. Benitec Biopharma has a 52-week low of $2.69 and a 52-week high of $12.89. The firm has a market cap of $95.18 million, a PE ratio of -5.32 and a beta of 0.90. The company’s 50 day moving average is $9.09 and its two-hundred day moving average is $8.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BNTC. GAMMA Investing LLC raised its position in shares of Benitec Biopharma by 20.3% during the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 1,102 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in Benitec Biopharma during the second quarter worth approximately $5,881,000. Simplify Asset Management Inc. purchased a new stake in shares of Benitec Biopharma during the 2nd quarter worth approximately $358,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock valued at $1,266,000 after buying an additional 64,092 shares in the last quarter. 52.19% of the stock is owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.